46 related articles for article (PubMed ID: 9637775)
1. Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy.
Wadkins RM; Danks MK; Horowitz L; Baker SD
Exp Cell Res; 1998 Jun; 241(2):332-9. PubMed ID: 9637775
[TBL] [Abstract][Full Text] [Related]
2. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
3. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Danks MK; Garrett KE; Marion RC; Whipple DO
Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418
[TBL] [Abstract][Full Text] [Related]
4. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
[TBL] [Abstract][Full Text] [Related]
5. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
6. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.
Baker SD; Wadkins RM; Stewart CF; Beck WT; Danks MK
Cytometry; 1995 Feb; 19(2):134-45. PubMed ID: 7743894
[TBL] [Abstract][Full Text] [Related]
8. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
Vanhoefer U; Müller MR; Hilger RA; Lindtner B; Klaassen U; Schleucher N; Rustum YM; Seeber S; Harstrick A
Br J Cancer; 1999 Dec; 81(8):1304-10. PubMed ID: 10604726
[TBL] [Abstract][Full Text] [Related]
9. Redistribution of DNA topoisomerase II beta after in vitro stabilization of human erythroleukemic nuclei by heat or Cu++ revealed by confocal microscopy.
Neri LM; Martelli AM; Maraldi NM
Microsc Res Tech; 1997 Feb; 36(3):179-87. PubMed ID: 9080408
[TBL] [Abstract][Full Text] [Related]
10. Antitumour drugs impede DNA uncoiling by topoisomerase I.
Koster DA; Palle K; Bot ES; Bjornsti MA; Dekker NH
Nature; 2007 Jul; 448(7150):213-7. PubMed ID: 17589503
[TBL] [Abstract][Full Text] [Related]
11. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Griffith TS; Kemp TJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
[TBL] [Abstract][Full Text] [Related]
12. The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Zhang J; Cheng C; He CL; Zhou YJ; Cao Y
Cancer Invest; 2008 Jun; 26(5):456-63. PubMed ID: 18568767
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
14. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Bence AK; Mattingly CA; Burke TG; Adams VR
Cancer Chemother Pharmacol; 2004 Oct; 54(4):354-60. PubMed ID: 15197485
[TBL] [Abstract][Full Text] [Related]
15. Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Mo YY; Wang P; Beck WT
Exp Cell Res; 2000 May; 256(2):480-90. PubMed ID: 10772820
[TBL] [Abstract][Full Text] [Related]
16. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
19. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids.
Sobhani AM; Ebrahimi SA; Mahmoudian M
J Pharm Pharm Sci; 2002; 5(1):19-23. PubMed ID: 12042115
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
